The patient has been diagnosed with ___ and has been referred for the OICR Genomics ___ assay through the ____ study. This test uncovered ___ oncogenic mutations most commonly altered genes in ___ cancer (DOI:[10.1038/nature](https://www.nature.com/)). While there is no FDA-approved therapeutic option for this mutation in __, ___ are FDA-approved for treatment with ___. Copy Number Analysis returned ___ .  There are currently no therapies associated with these alterations. The tumour had an estimated ploidy of ___ and the mutational burden was ___ coding mutations per Mb, which is ___ (mean __ coding mutations/Mb, DOI:[DOI:10.1038/nature](https://www.nature.com/)).